Paclitaxel dose study using a 1-hour muscle-area infusion
Treatments studied
Part of Cancer, Digestive system, Skin clinical trials.
This trial studies how paclitaxel (a chemotherapy medicine) behaves in the body when given by a specific 1-hour infusion approach. It may help refine dosing for people with cancer using measurements from scans, and it includes a medicine schedule you must match.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You need planned paclitaxel 80 mg per square meter, given over 1 hour
- You must have a recent usable scan (CT, PET-CT, or MRI) within the last year for the chest, abdomen, or pelvis
- You must be female and at least 18 years old
- Your blood and organ tests must be good enough to safely receive paclitaxel (as defined in the study)
- You must understand the study and sign written consent
- You must not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests paclitaxel given as tiny micelle particles for people whose cancer (pancreatic, bile duct, lung, stomach, esophagus, or breast) stopped responding to taxane chemotherapy or did not shrink. The goal is to see if this treatment can help when standard taxanes no longer work.
This study tests whether a new version of paclitaxel (albumin-bound) works the same as the approved version in people with breast cancer. It's for patients whose cancer has spread or returned after other treatments, or those for whom this drug is recommended by treatment guidelines.
This early-phase study tests how epidiferphane works in the body and whether it is safe when combined with standard chemotherapy “taxanes” (paclitaxel or docetaxel) for breast cancer. If you qualify, you may be starting a new taxane treatment plan at the study site, and you would be followed closely for side effects and drug levels.
This study looks at how physical activity and body composition affect the side effects of paclitaxel, a chemotherapy drug, in women with stage II or III breast cancer. It aims to help doctors understand who might have more or fewer side effects during treatment.
This trial gives weekly paclitaxel chemotherapy before breast surgery, then studies tumor “biomarkers” to see how well treatment is working. The goal is to improve how doctors predict which patients benefit and who may need different approaches.
This trial tests a new form of paclitaxel (a chemotherapy drug) wrapped in tiny fat bubbles called liposomes. It is given directly into an artery that feeds the tumor, which may deliver the drug more effectively to the cancer. The study is for people with advanced solid tumors that can be treated this way, such as stomach, liver, pancreatic, or lung cancers.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.